Today, patients on insulin receive injections daily, or even more often, but both companies are working to change that.

Eli Lilly LLY announced positive topline results from two phase III studies, QWINT-1 and QWINT-3, which evaluated efsitora ...

Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly ...

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in ...

In the trial, efsitora met the primary endpoint of non-inferior A1C reduction. For the efficacy estimand, efsitora reduced A1C by 1.34% compared to 1.26% for insulin degludec resulting in an A1C of ...

Eli Lilly said a once-weekly dose of insulin efsitora proved to reduce hemoglobin A1C in a Qwint-2 Phase 3 trial when compared with a daily dose of insulin in people with type 2 diabetes using insulin ...

Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs ...

Eli Lilly also announced an $800 million facility expansion in Kinsale, Ireland. That site started to manufacture drugs last year to help meet demand for the company's diabetes and obesity ...

(RTTNews) - Eli Lilly and Co. (LLY ... per patient-year of exposure of 0.58 with efsitora vs. 0.45 with insulin degludec. The company noted that estimated combined rates of severe or clinically ...